Visiopharm

company

About

Visiopharm image analysis and stereology software has become the preferred Quantitative Digital Pathology solution.

  • 11 - 50

Details

Last Funding Type
Series Unknown
Industries
Health Care,Health Diagnostics,Software
Founded date
Jan 1, 2001
Number Of Employee
11 - 50
Operating Status
Active

Visiopharm image analysis and stereology software has become the preferred Quantitative Digital Pathology solution for leading biopharmaceutical companies, contract research organizations (CRO), academic medical centers, research institutes, and hospitals all over the world. Recently, Visiopharm has expanded to include ONCOtopix™ Dx a robust solution for cancer diagnostics with CE-IVD algorithms for the breast panel, integrated LIS driven workflow, and Virtual Double Staining. Their software is featured in over 800 scientific publications, and is compatible with leading slide scanner manufacturers, data management software, and a wide variety of microscopes and cameras.

Visiopharm, a privately owned company, was founded in 2001 by the Managing Director, and Chief Executive Officer, Michael Grunkin and the Chief Technical officer, Johan Doré Hansen, who both have a strong scientific and practical background in image analysis.

Their company has grown into an international business with over 500 licenses in more than 30 countries. Their growing network of authorized distributors and partners support the growth of Visiopharm solutions on several continents including North America, Europe and Asia. Their headquarters is located in the Medicon Valley of Denmark, with a branch office in the Netherlands, and a North America office in Broomfield, Colorado.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
kr95M
Visiopharm has raised a total of kr95M in funding over 2 rounds. Their latest funding was raised on Sep 1, 2020 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 1, 2020 Series Unknown 2 Detail
Aug 23, 2018 Series Unknown kr95M 1 Detail
Oct 5, 2007 Series Unknown 1 Northcap Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Visiopharm is funded by 2 investors. C.L. Davids Fond and Northcap are the most recent investors.
Investor Name Lead Investor Funding Round
C.L. Davids Fond Series Unknown
Northcap Series Unknown